Cargando…

Osimertinib Resistance: Molecular Mechanisms and Emerging Treatment Options

SIMPLE SUMMARY: Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is currently indicated as first-line therapy in patients with non-small-cell lung cancer (NSCLC) and sensitizing EGFR mutations; as second-line therapy in patients who present the resis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gomatou, Georgia, Syrigos, Nikolaos, Kotteas, Elias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913144/ https://www.ncbi.nlm.nih.gov/pubmed/36765799 http://dx.doi.org/10.3390/cancers15030841

Ejemplares similares

Emerging therapies in thymic epithelial tumors (Review)
por: Dapergola, Athina, et al.
Publicado: (2023)

Tumor Dormancy: Implications for Invasion and Metastasis
por: Gomatou, Georgia, et al.
Publicado: (2021)

The Role of REV-ERB Receptors in Cancer Pathogenesis
por: Gomatou, Georgia, et al.
Publicado: (2023)

An overview of the role of telomeres and telomerase in pre‑neoplastic lesions (Review)
por: Karaviti, Eleftheria, et al.
Publicado: (2023)

Programmed Death-Ligand 1 as a Regulator of Tumor Progression and Metastasis
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Profile of capecitabine/temozolomide combination in the treatment of well-differentiated neuroendocrine tumors
por: Kotteas, Elias A, et al.
Publicado: (2016)

CD24: A Novel Target for Cancer Immunotherapy
por: Panagiotou, Emmanouil, et al.
Publicado: (2022)

Assessment of Seroconversion after SARS-CoV-2 Vaccination in Patients with Lung Cancer
por: Trontzas, Ioannis P., et al.
Publicado: (2022)

Estrogen-Receptor-Low-Positive Breast Cancer: Pathological and Clinical Perspectives
por: Malainou, Christina Panagiotis, et al.
Publicado: (2023)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Acquired Mechanisms of Resistance to Osimertinib—The Next Challenge
por: Ríos-Hoyo, Alejandro, et al.
Publicado: (2022)

Crazy paving pattern as a rare radiological manifestation of peripheral T-cell lymphoma (PTCL) with lung involvement: A case report
por: Gomatou, Georgia, et al.
Publicado: (2018)

Programmed Cell Death Protein 1 Axis Inhibition in Viral Infections: Clinical Data and Therapeutic Opportunities
por: Tsiakos, Konstantinos, et al.
Publicado: (2022)

189P Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer
por: Trontzas, I.P., et al.
Publicado: (2022)

Drug-resistant tuberculosis: emerging treatment options
por: Adhvaryu, Meghna, et al.
Publicado: (2011)

Significant Increase in Blood Pressure Following BNT162b2 mRNA COVID-19 Vaccination among Healthcare Workers: A Rare Event
por: Syrigos, Nikolaos, et al.
Publicado: (2022)

A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance
por: Qu, Fanjie, et al.
Publicado: (2021)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Molecular Mechanisms and Current Treatment Options for Cancer Cachexia
por: Ahmad, Syed Sayeed, et al.
Publicado: (2022)

Emerging Treatment Options for Multi-Drug-Resistant Bacterial Infections
por: Giurazza, Roberto, et al.
Publicado: (2021)

Malignant Superior Vena Cava Syndrome: State of the Art
por: Patriarcheas, Vasileios, et al.
Publicado: (2022)

AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
por: Taniguchi, Hirokazu, et al.
Publicado: (2019)

Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib
por: Lim, Sun Min, et al.
Publicado: (2021)

Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance
por: Marin, Jose J. G., et al.
Publicado: (2021)

Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options
por: Andravizou, Athina, et al.
Publicado: (2019)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models
por: Lim, Sun Min, et al.
Publicado: (2022)

Emerging Treatment Options for Infections by Multidrug-Resistant Gram-Positive Microorganisms
por: Koulenti, Despoina, et al.
Publicado: (2020)

Takotsubo Cardiomyopathy in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Summary of Included Cases
por: Trontzas, Ioannis P., et al.
Publicado: (2023)

Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
por: Yalamarty, Satya Siva Kishan, et al.
Publicado: (2023)

Osimertinib: A Novel Therapeutic Option for Overcoming T790M Mutations in Non–Small Cell Lung Cancer
por: Li, Shan, et al.
Publicado: (2017)

Finding chinks in the osimertinib resistance armor
por: Leal, Jose Luis, et al.
Publicado: (2020)

Emerging treatment options for nasopharyngeal carcinoma
por: Zhang, Lu, et al.
Publicado: (2013)

Emerging systemic treatment options in meningioma
por: Mair, Maximilian J., et al.
Publicado: (2022)

Feiyanning formula modulates the molecular mechanism of osimertinib resistance in lung cancer by regulating the Wnt/β-catenin pathway
por: Sang, Shuliu, et al.
Publicado: (2022)

Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial
por: Miura, Satoru, et al.
Publicado: (2023)

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data
por: Lee, Chung-Shien, et al.
Publicado: (2021)

Osimertinib Rechallenge With Bevacizumab vs. Chemotherapy Plus Bevacizumab in EGFR-Mutant NSCLC Patients With Osimertinib Resistance
por: Cui, Qingli, et al.
Publicado: (2022)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Molecular Targets and Emerging Therapeutic Options for Uterine Leiomyosarcoma
por: Miller, Heather, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_071d7ovqhvtol7d0jqtbn52g5k